Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy.

Bankó Z, Pozsgay J, Gáti T, Rojkovich B, Ujfalussy I, Sármay G.

Clin Immunol. 2017 Nov;184:63-69. doi: 10.1016/j.clim.2017.05.012. Epub 2017 May 12.

PMID:
28506920
2.

Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective.

Péntek M, Rojkovich B, Czirják L, Géher P, Keszthelyi P, Kovács A, Kovács L, Szabó Z, Szekanecz Z, Tamási L, Tóth ÁE, Ujfalussy I, Hevér NV, Strbák B, Baji P, Brodszky V, Gulácsi L.

Eur J Health Econ. 2014 May;15 Suppl 1:S73-82. doi: 10.1007/s10198-014-0596-2. Epub 2014 May 16.

PMID:
24832838
3.

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).

Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA.

Ann Rheum Dis. 2013 Jun;72(6):986-91. doi: 10.1136/annrheumdis-2012-201341. Epub 2012 Jul 13.

PMID:
22798567
4.

Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernàndez-Sueiro JL, Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D'Angelo S, Vacca A, VAN Kuijk AW, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group.

J Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15.

PMID:
21324965
5.

Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey.

Brodszky V, Péntek M, Bálint PV, Géher P, Hajdu O, Hodinka L, Horváth G, Koó E, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L.

Scand J Rheumatol. 2010 Aug;39(4):303-9. doi: 10.3109/03009740903468982.

PMID:
20166848
6.

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.

Brodszky V, Bálint P, Géher P, Hodinka L, Horváth G, Koó É, Péntek M, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L.

Rheumatol Int. 2009 Dec;30(2):199-205. doi: 10.1007/s00296-009-0936-1.

PMID:
19381635
7.

Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.

Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Géher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T; QUEST-RA Group.

Arthritis Res Ther. 2009;11(1):R7. doi: 10.1186/ar2591. Epub 2009 Jan 14.

8.

Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis.

György B, Tóthfalusi L, Nagy G, Pásztói M, Géher P, Lörinc Z, Polgár A, Rojkovich B, Ujfalussy I, Poór G, Pócza P, Wiener Z, Misják P, Koncz A, Falus A, Buzás EI.

Arthritis Res Ther. 2008;10(5):R110. doi: 10.1186/ar2507. Epub 2008 Sep 12.

9.

Clinical and genetic registries in psoriatic disease.

Gladman DD, Rahman P, Krueger GG, Mease PJ, Qureshi AA, Dutz JP, Lindqvist U, Carneiro S, Helliwell PS, Ujfalussy I, Gottlieb AB, Behrens F, Ståhle M.

J Rheumatol. 2008 Jul;35(7):1458-63.

PMID:
18609745
10.

[Psoriatic arthritis].

Ujfalussy I.

Orv Hetil. 2007 Nov 11;148(45):2152-3. Hungarian. No abstract available.

PMID:
17984028
11.

[The role of biological agents in the treatment of psoriatic arthritis, literature review].

Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L.

Orv Hetil. 2006 Oct 15;147(41):1963-70. Review. Hungarian.

PMID:
17120686
12.
13.

Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases.

Polgár A, Falus A, Koó E, Ujfalussy I, Seszták M, Szuts I, Konrád K, Hodinka L, Bene E, Mészáros G, Ortutay Z, Farkas E, Paksy A, Buzás EI.

Rheumatology (Oxford). 2003 Apr;42(4):522-7.

PMID:
12649398
14.

Measurement of disease activity in psoriatic arthritis. Extended report.

Ujfalussy I, Koó E.

Z Rheumatol. 2003 Feb;62(1):60-5.

PMID:
12624805
15.

Systemic, secondary amyloidosis in a patient with psoriatic arthritis.

Ujfalussy I, Bély M, Koó E, Seszták M.

Clin Exp Rheumatol. 2001 Mar-Apr;19(2):225. No abstract available.

PMID:
11326492
16.

Termination of disease modifying antirheumatic drugs in psoriatic arthritis.

Ujfalussy I, Koó E, Seszták M.

J Rheumatol. 2001 Mar;28(3):682-3. No abstract available.

PMID:
11296986
17.

Subsets in psoriatic arthritis formed by cluster analysis.

Koó T, Nagy Z, Seszták M, Ujfalussy I, Merétey K, Böhm U, Forgács S, Szilágyi M, Czirják L, Farkas V.

Clin Rheumatol. 2001;20(1):36-43.

PMID:
11254239
18.

[Drugs that induce and/or worsen psoriasis].

Koó E, Seszták M, Gyulai F, Ujfalussy I.

Orv Hetil. 1988 Aug 7;129(32):1699-701. Review. Hungarian. No abstract available.

PMID:
2902548

Supplemental Content

Loading ...
Support Center